Ponatinib, another multi-targeted receptor tyrosine kinase inhibitor, is FDA-approved for chronic myelogenous leukemia that has failed to respond to first-line inhibitors. This evidence concerns the gene NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive.